Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs

Bone Marrow Transplantation
P G GobbiG R Corazza

Abstract

There is great interest in chemotherapies for relapsed or refractory lymphomas that are both directly effective against the lymphoma and able to mobilize PBSCs for rescue after high-dose chemotherapy (HDC). Twenty-eight patients with relapsed or refractory lymphomas were treated with a shortened, intensified MJMA regimen (mitoxantrone 10 mg/m(2) i.v. day 1, carboplatin 200 mg/m(2) i.v. days 1-2, methylprednisolone 500 mg/m(2) i.v. days 1-3, cytarabine 2000 mg/m(2) i.v. day 3) for six cycles every 21 days. A median of five cycles/patient was administered. Nineteen patients had complete responses, seven partial responses and two no responses. The only remarkable toxicity was hematological. In 18 patients who were candidates for HDC, a mean of 10.45 x 10(6) CD34/kg of patients' body weight was collected (range: 3.70-24.88 x 10(6)/kg). Eleven patients underwent transplantation, which converted two of four partial responses into complete responses. The median follow-up was 49 months. Survival parameters were not related to relapsed/refractory status or to the time from the last chemotherapy, but were related only weakly to the number of prior chemotherapies. Outpatient MJMA is a feasible and very effective salvage chemotherapy per s...Continue Reading

References

Oct 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D O DixonE A Gehan
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Sep 21, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E O La BarberaS Sica
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Aug 30, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Basak OyanEmin Kansu
May 17, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M S HertzbergK F Bradstock
Oct 5, 2006·The Korean Journal of Internal Medicine·Sang Hyoung ParkCheolwon Suh
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Oct 3, 2007·Hematology/oncology Clinics of North America·David A Macdonald, Joseph M Connors
Oct 3, 2007·Hematology/oncology Clinics of North America·Volker DiehlDaniel Re
Oct 3, 2007·Hematology/oncology Clinics of North America·George P Canellos

❮ Previous
Next ❯

Citations

Jul 20, 2010·British Journal of Haematology·Morie A Gertz
Apr 22, 2017·Pharmaceutical Biology·Itzen Aguiñiga-SánchezRamón Marcos Soto-Hernández

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.